Leads Biolabs

Leads Biolabs is a clinical-stage biotechnology company founded in 2012 by medical scientists Dr. Shoupeng Lai and Dr. Xiaoqiang Kang. The founders met at the U.S. National Cancer Institute (NCI), where they shared an interest in tumor immunology. Dr. Lai previously conducted research at Georgetown University's Lombardi Cancer Center and worked at Nasdaq-listed GenVec, Inc. and Tokyo Stock Exchange-listed AnGes, Inc. Dr. Kang has over 16 years of experience in antibody drug development, including time as a principal scientist at Eli Lilly, and was involved in the development of Erbitux.

The company focuses on discovering, developing, and commercializing therapies for oncology, autoimmune conditions, and other severe diseases in China and globally. Its business model is integrated, covering the entire drug development lifecycle from early-stage discovery and preclinical research to clinical development, chemistry, manufacturing, and controls (CMC), and pilot manufacturing. Leads Biolabs has developed a pipeline of 14 drug candidates, with six in clinical trials. The company's strategy involves developing assets in immuno-oncology, T-cell engagers (TCEs), and antibody-drug conjugates (ADCs). Its R&D is driven by proprietary technology platforms, including the AI-powered LeadsBody™ (a CD3 T-cell engager platform), X-body™ (a 4-1BB engager platform), and a linker-payload platform for ADCs.

Revenue is generated through strategic partnerships, including out-licensing, co-development agreements, and forming joint ventures. For instance, Leads Biolabs partnered with Aditum Bio to create Oblenio Bio, which licensed an exclusive option for LBL-051, a tri-specific T-cell engager antibody, in a deal including a $35 million upfront payment and up to $579 million in milestones. Another collaboration is with BiOneCure Therapeutics to jointly develop ADCs for solid tumors. On July 25, 2025, Leads Biolabs listed on the Hong Kong Stock Exchange (HKEX: 9887), raising approximately $189 million to fund clinical trials, advance preclinical assets, upgrade manufacturing capabilities, and for general corporate purposes.

Keywords: immuno-oncology, antibody therapies, autoimmune diseases, clinical-stage biotechnology, T-cell engagers, antibody-drug conjugates, bispecific antibodies, cancer immunotherapy, monoclonal antibodies, oncology therapeutics, drug discovery, clinical development, LBL-024, PD-L1, 4-1BB, solid tumors, hematologic malignancies, GPRC5D, LAG-3, biopharmaceuticals